Legal Representation
Attorney
Christina M. Licursi
USPTO Deadlines
Next Deadline
1843 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20250225)
Due Date
February 25, 2031
Grace Period Ends
August 25, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
23 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 25, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Feb 25, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jan 31, 2025 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Jan 31, 2025 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Jan 4, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Oct 17, 2024 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Jan 4, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Oct 17, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Aug 27, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 27, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Aug 27, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Aug 27, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 27, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jan 2, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jan 2, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 26, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Dec 26, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Dec 26, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Dec 13, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 29, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 28, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 27, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 2, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Encapsulated nucleic acids for use as biological therapeutics in gene therapy for the treatment of rare genetic disorders, cardiovascular diseases, respiratory diseases, infectious diseases, retinal diseases, metabolic disorders, hormonal deficiencies, endocrine diseases, eye diseases and disorders, intestinal diseases, autoimmune diseases, autoinflammatory diseases, inflammatory disorders, musculoskeletal diseases, neurological disorders, hematologic conditions, cutaneous conditions, neurodegenerative diseases, congenital disorders, kidney and urinary diseases, reproductive diseases, mitochondrial diseases, lung disorders, immune system diseases, mouth diseases, digestive diseases; pharmaceutical preparations for use in the prevention, diagnosis and treatment of disease, namely, rare genetic disorders, cardiovascular diseases, respiratory diseases, infectious diseases, retinal diseases, metabolic disorders, hormonal deficiencies, endocrine diseases, eye diseases and disorders, intestinal diseases, autoimmune diseases, autoinflammatory diseases, inflammatory disorders, musculoskeletal diseases, neurological disorders, hematologic conditions, cutaneous conditions, neurodegenerative diseases, congenital disorders, kidney and urinary diseases, reproductive diseases, mitochondrial diseases, lung disorders, immune system diseases, mouth diseases, digestive diseases; pharmaceutical preparations for use in gene therapy
First Use Anywhere:
Sep 16, 2024
First Use in Commerce:
Sep 16, 2024
Classification
International Classes
005